Clinical trial
HP184 in Chronic Spinal Cord Injury Subjects
NCT00093275 · Sanofi, Industry · Completed
Key facts
| NCT number | NCT00093275 |
|---|---|
| Title | HP184 in Chronic Spinal Cord Injury Subjects |
| Official title | A Phase II, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of HP184 Administered Orally Once Daily for Twenty-Four Weeks in Adult Subjects With Chronic Spinal Cord Injury (CSCI) |
| Lead sponsor | Sanofi, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Spinal Cord Injury |
| Intervention type | Drug |
| Interventions | HP184 |
| Enrollment | 262 |
| Start date | Oct 1, 2004 |
| Primary completion | Dec 1, 2005 |
| Completion | Dec 1, 2005 |
| First posted | Oct 7, 2004 |
| Last update posted | Aug 21, 2008 |
| Countries | Australia, Germany, India, United Kingdom, United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: